Key Points Surrozen reported GAAP EPS of $2.55 for Q2 2025, exceeding expectations by $3.66 per share (GAAP) due to significant one-time and non-cash gains. Surrozen recorded $1.0 million in research ...

Patent Issuance: In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 by the U.S. Patent and Trademark Office, covering its SWAP™ technology for creating multi-specific Wnt surrogate molecules ...

Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for ...

Investigators crafted a classification for age-related macular degeneration (AMD) based on optical coherence tomography (OCT) ...

Beauty expert Nadine Baggott, who regularly appears on This Morning, is known for her in-depth skincare knowledge and stunning complexion ...

Opal, a Hanceville woman who recently turned 100, received a video magnifier as a birthday gift, allowing her to read again ...

FEHA is developed to adaptively recalibrate the importance of feature elements by assigning fuzzy weights across both channel and spatial domains, which can enhance the model's ability to learn the ...

Asymmetry between the superior and inferior retinal hemispheres — as detected using optical coherence tomography (OCT) — can help diagnose and determine stages of normal tension glaucoma (NTG), ...

Known for its anti-inflammatory, anti-fibrotic, and neuroregenerative properties, hAM has been successfully employed in “repair [ing] photoreceptors, restor [ing] normal retinal structures, and clos ...

Background Coronary artery disease (CAD) is linked to an increased risk of mild cognitive impairment (MCI). Effective and convenient screening methods for identifying MCI from the CAD population are ...

Anti-VEGF injections are the first-line treatment for exudative AMD; however, it is unknown if suppressing VEGF with repeated injections over the long term has any effect on the normal retinal ...

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.